Drug Profile


Alternative Names: CI 1004; Darbufelone mesylate; PD 136095-0073

Latest Information Update: 04 Jul 2002

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Small molecules; Thiazolidines
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatic disorders

Most Recent Events

  • 04 Jul 2002 No development reported - Phase-III for Rheumatic disorders in USA (PO)
  • 12 Jul 2000 A study in patients with rheumatoid arthritis has been added to the adverse events section
  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top